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Background: Acute exacerbations of chronic bronchitis (AECB), including chronic obstructive pulmonary disease
(AECOPD), represent a substantial patient burden. Few data exist on outpatient antibiotic management for AECB/
AECOPD in Eastern/South Eastern Europe, in particular on the use of moxifloxacin (AveloxW), although moxifloxacin
is widely approved in this region based on evidence from international clinical studies.
Methods: AVANTI (AVeloxW in Acute Exacerbations of chroNic bronchiTIs) was a prospective, observational study
conducted in eight Eastern European countries in patients > 35 years with AECB/AECOPD to whom moxifloxacin
was prescribed. In addition to safety and efficacy outcomes, data on risk factors and the impact of exacerbation on
daily life were collected.
Results: In the efficacy population (N = 2536), chronic bronchitis had been prevalent for > 10 years in 31.4% of
patients and 66.0% of patients had concomitant COPD. Almost half the patients had never smoked, in contrast to
data from Western Europe and the USA, where only one-quarter of COPD patients are non-smokers. The mean
number of exacerbations in the last 12 months was 2.7 and 26.3% of patients had been hospitalized at least once
for exacerbation. Physician compliance with the recommended moxifloxacin dose (400 mg once daily) was 99.6%.
The mean duration of moxifloxacin therapy for the current exacerbation (Anthonisen type I or II in 83.1%;
predominantly type I) was 6.4 ± 1.9 days. Symptom improvement was reported after a mean of 3.4 ± 1.4 days. After
5 days, 93.2% of patients reported improvement and, in total, 93.5% of patients were symptom-free after 10 days. In
the safety population (N = 2672), 57 (2.3%) patients had treatment-emergent adverse events (TEAEs) and 4 (0.15%)
had serious TEAEs; no deaths occurred. These results are in line with the known safety profile of moxifloxacin.
Conclusions: A significant number of patients in this observational study had risk factors for poor outcome,
justifying use of moxifloxacin. The safety profile of moxifloxacin and its value as an antibiotic treatment were
confirmed. Physicians complied with the recommended 400 mg once-daily dose in a large proportion of patients,
confirming the advantages of this simple dosing regimen.
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Acute exacerbations of chronic bronchitis (AECB), inclu-
ding chronic obstructive pulmonary disease (AECOPD),
represent a substantial disease burden to patients, contri-
buting to reduced lung function, increased morbidity and
mortality, and long-term impairment in quality of life [1-8].
A role for bacteria is implicated in 40-50% of AECB
episodes [9]. In a routine clinical setting, where bacterio-
logical assessment may not be available, empirical antibac-
terial therapy is generally recommended for patients who
fulfill specific clinical criteria, with the aim to influence
the disease course and prevent complications [10-12].
Guidelines by Woodhead et al. [12] recommend antibiotic
therapy for patients with increased dyspnea, sputum
volume, and sputum purulence (Anthonisen type I) and
for patients with two of these symptoms including
increased sputum purulence (Anthonisen type II), but not
in patients with one of these symptoms alone (Anthonisen
type III) [13]. The GOLD recommendations for antibiotic
therapy are based on the severity of exacerbations, the pres-
ence of risk factors, and predictors of poor outcome
(e.g. comorbid conditions, frequency of AECBs, and previ-
ous antibiotic use) [10]. Using these criteria, the GOLD
guidelines recommend amoxicillin/clavulanate or fluoroqui-
nolones in patients with moderate to severe exacerbations.
Moxifloxacin is a fourth-generation fluoroquinolone
with a broad spectrum of activity relevant to the microor-
ganisms isolated in AECB, including Gram-positive and
Gram-negative bacteria, atypical pathogens, and anaerobic
bacteria, as well as species resistant to aminoglycosides,
tetracyclines, and macrolide antibiotics. Beta-lactamase
producing strains of Haemophilus influenzae and Morax-
ella catarrhalis are susceptible to moxifloxacin [14-17].
Moxifloxacin is strongly targeted to alveolar tissue [18,19]
and demonstrates rapid initial killing and eradication rates
for pneumococcal bacteria [16].
The initial clinical program for moxifloxacin in AECB
included two studies of moxifloxacin (400 mg once
daily, 5 days) versus clarithromycin (500 mg twice
daily, 7–10 days) and two studies versus cefuroxime
axetil (500 mg twice daily, 10 days) in a total of 2381
patients [20,21]. Together, these studies demonstrated
that moxifloxacin achieved a clinical response rate of 89%
and a bacteriological response rate of 87% at 7–14 days
post-treatment.
In another, prospective, multicenter, randomized, double-
blind study of outpatients with AECB (MOSAIC), 5-day
moxifloxacin was associated with significantly higher
clinical cure rates and bacterial eradication rates than a
7-day standard regimen (i.e. amoxicillin 500 mg three
times daily, or clarithromycin 500 mg twice daily, or
cefuroxime axetil 250 mg twice daily) [22]. In addition,
the time until next exacerbation was significantly greater
with moxifloxacin than the comparator during 9-monthfollow-up [22], which may be attributed to more effective
bacterial eradication by moxifloxacin [23]. Post-hoc ana-
lyses of the MOSAIC study identified a beneficial influ-
ence on clinical cure rates from moxifloxacin treatment
and a poorer outcome associated with cardiopulmonary
disease, forced expiratory volume in 1 second (FEV1)
< 50% predicted, and ≥ 4 AECBs in the previous year [24].
The recent MAESTRAL study of 1492 outpatients
aged ≥ 60 years with moderate-to-severe AECOPD (Antho-
nisen grade I) showed that moxifloxacin (400 mg/day for
5 days) is as effective as amoxicillin/clavulanic acid (875/
125 mg for 7 days) in clinical success rate, with a
significantly lower failure rate in patients with confirmed
bacterial AECOPD [25]. The benefits of moxifloxacin
(400 mg/day for 5 days) also translated into a more favor-
able long-term quality of life when compared with amoxi-
cillin/clavulanate (500/125 mg three times daily for
10 days) in the general practice setting [26].
Based on the existing controlled trial evidence, researc-
hers have concluded that moxifloxacin is as effective or
even more effective compared with other antimicrobials,
with a more advantageous dosage regimen that may be
associated with increased compliance [27,28].
Observational studies provide valuable information,
alongside controlled clinical studies, with relevance to
contemporary practice. Published data on 9225 patients
aged ≥ 35 years with AECB or AECOPD from eight
European countries, from among the 46 893 patients
recruited globally to an observational study of moxiflox-
acin (the GIANT study), demonstrated very good or
good efficacy for moxifloxacin in 94.9% of patients and
very good or good tolerability in 96.7%, based on phys-
ician assessments [29].
Few data exist on the outpatient antibiotic management
of AECB/AECOPD in Eastern/South Eastern Europe,
and in particular on the use of moxifloxacin in this
population. The current non-interventional observa-
tional study was conducted to gain further information
on the treatment of AECB with moxifloxacin in a large
population of outpatients with moderate-to-severe




The AVANTI study (AVeloxW in Acute Exacerbations of
chroNic bronchiTIs) was a prospective, multicenter,
observational study conducted at 182 investigational
centers in 8 countries (Albania, Bosnia and Herzegovina,
Kazakhstan, Macedonia, Moldova, Russian Federation,
Slovakia, and Ukraine) between 8 April 2008 and 6 April
2010.
The observational period for each patient commenced
at the initiation of treatment with moxifloxacin (AveloxW)
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relief of symptoms at follow-up visit or premature discon-
tinuation. Up to two follow-up visits were planned,
with the last assessment following the final intake of
moxifloxacin.
Patients
Male or female outpatients aged ≥ 35 years with a diag-
nosis of AECB were included in the study. The diagnosis
of AECB and of any concomitant diseases was provided
by attending physicians, who were pulmonologists or in-
ternal medicine specialists (approximately 60%), general
practitioners (10%), or practitioners from other special-
ties. An exacerbation of chronic bronchitis was consid-
ered to be present when the patient experienced an
acute increase in respiratory symptoms, including dys-
pnea, sputum volume, and/or sputum clearance. Exacer-
bations were classified into Anthonisen types I, II, or III
[13]. Exclusion criteria were limited to contraindications
to the use of moxifloxacin, as described in the locally
available Summary of Product Characteristics.
Data on disease characteristics, risk factors, and the
impact of exacerbations on daily life were collected from
patients before initiation of moxifloxacin treatment.
The study protocol was approved by the local inde-
pendent ethics committee or institutional review board,
as applicable, at each of the investigator sites. At the
national level, the study was approved in Albania by the
Bioethics National Committee of the Ministry of Health,
in Moldova by the National Ethical Committee, in the
Russian Republic by the Ethical Committee at the
Federal Service on Surveillance in Healthcare and Social
Development, in Slovakia by the Ethical Committee of
the Bratislava Region, and in Ukraine by the Central
Ethics Commission of the Ministry of Health. Notifica-
tion on the study protocol, following regulatory require-
ments for non-interventional studies, was provided in
Bosnia and Herzegovina to the Ministry of Health, and
in Kazakhstan to the local regulatory authority and the
National Center for Drug Expertise, Medical Devices and
Medical Equipment. In Macedonia, no ethics committee
approval or notification was requested at national level.
All patients provided informed consent in accordance
with local regulations.
Study medication
Moxifloxacin was prescribed according to the medical
judgment of the investigator and in accordance with the
guidelines from the European Medicines Agency, the US
Food and Drug Administration, and local regulations (e.g.
AveloxW (moxifloxacin hydrochloride) US prescribing
information [30]).
The dose of moxifloxacin recommended for the treat-
ment of AECB in the study was 400 mg once daily,consistent with the local Summary of Product Charac-
teristics. Final decisions on the dose of moxifloxacin and
on the use of concomitant medications were at the dis-
cretion of the attending physician.
Efficacy and safety assessments
Efficacy assessments for each patient included the fre-
quency of improvement of different symptoms (including
sputum volume, sputum character, fever, cough, and dys-
pnea), the frequency of cure (i.e. symptom-free status), the
time to improvement in symptoms and to cure, and
general assessments of the effectiveness of moxifloxacin
treatment using methodologies similar to those employed
in the GIANT study [29].
Safety evaluations included adverse events reported
during the study, coded using the Medical Dictionary for
Regulatory Activities (MedDRA) version 13.0, and a gen-
eral subjective tolerability assessment by investigators.
Physicians additionally provided summary assessments
of the overall efficacy and tolerability of moxifloxacin
into the categories: ‘very good’, ‘good’, ‘sufficient’, and
‘insufficient’. Both physicians and patients provided an
assessment of their satisfaction with the therapeutic ef-
fect of moxifloxacin. Finally, for patients with available
data, physicians compared the overall effect and onset of
action of moxifloxacin against the antibiotic used to
treat the previous episode of AECB.
Statistical analyses
Efficacy and safety outcomes were analyzed by descrip-
tive statistics. As appropriate for non-interventional
studies, statistical tests were not performed. The safety
population included all patients who took at least one
dose of study medication and provided information on
adverse events. The efficacy population included all
patients who took at least one dose of study medication
and provided information on the efficacy of treatment.
A minimum of 1600 patients were planned to be
included in the study. As 2672 patients were actually
included, adverse events occurring at a frequency of




A total of 2672 patients were enrolled in the study and
included in the safety population. The efficacy popula-
tion consisted of 2536 patients, after exclusion of 136
(5.1%) patients from the safety population, most com-
monly because of age < 35 years (n = 119) (Figure 1).
Demographic and disease characteristics of the efficacy
population at baseline are presented in Table 1. Patient
ages ranged from 35 to 94 years, with approximately
one-third of patients (31.6%) aged above 65 years. Over
Figure 1 Patient disposition.
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kers. Over the past 12 months, patients had experienced a
mean of 2.7 ± 1.9 (range 1.0-20.0) episodes of AECB. An
antibiotic was prescribed for the previous episode of
AECB in 62.2% of patients, most commonly amoxicillin
(13.6% of patients), usually combined with clavulanic acid.
The most common symptoms in the current AECB
episode were increased sputum purulence, worsening of
dyspnea, and increased sputum volume (Table 1); 42.9%
of patients were classified as Anthonisen type I, 40.2% as
type II, and 16.2% as type III, with data missing in the
remainder (Table 1). One-half of patients (49.9%) com-
plained of an infection of the upper respiratory tract in
the past 5 days. An impact on daily life activities was
reported by 90.4%, over a mean duration of 6.6 ± 5.5 days.
Sleep disturbances were reported by 68.6% of patients,
with impact on a mean of 4.1 ± 3.7 nights. The impact of
the current AECB episode on daily activities and sleep
disturbance in patient subgroups categorized by gender,
age, smoking status, concomitant diseases, Anthonisen
grade, and number of severe symptoms is presented in
Table 2. Mean FEV1 (measured in 1261 patients) was
2.0 ± 0.9 liters. Patients experienced AECB symptoms for
a mean of 7.0 ± 5.0 days before initiation of treatment
with moxifloxacin.
Concomitant diseases of special interest recorded by
investigators included COPD (66.0% of patients), emphy-
sema (23.8%), asthma (16.6%), cardiac ischemia (23.1%),
cor pulmonale (10.6%), and diabetes (10.1%). Concomi-
tant medications were taken by 93.3% of patients, mostcommonly a corticosteroid (32.8% overall, including
40.8% of Anthonisen type I, 28.0% of type II, and 24.2%
of type III patients); the mucolytic ambroxol (18.8%);
and the mucolytic/antioxidant, acetylcysteine (18.6%). As
expected, a large proportion of patients (83.4%) received
comedications to treat their respiratory symptoms.
The most frequently used non-AECB-related comedica-
tions were for the treatment of cardiovascular symptoms
(36.1% of patients), dermatological diseases (23.0%), dys-
function of the alimentary tract and metabolism (22.2%),
and ophthalmological diseases (20.5%).
Moxifloxacin treatment
Moxifloxacin was administered at the recommended
dose of 400 mg once daily in 99.6% (n = 2526) of en-
rolled patients, with a higher dose of 600 mg/day (n = 5)
or 800 mg/day (n = 5) in the remainder.
The mean (SD) duration of moxifloxacin treatment
was 6.4 ± 1.9 days (range: 1.0-15.0 days) in the efficacy
population; 55.2% of patients were treated for 5 days,
29.1% for 7 days, and 14.0% for 10 days. Mean dura-
tions of treatment in patients with Anthonisen type I, type
II, and type III AECB were 6.4 ± 1.9, 6.4 ± 1.9, and 6.2 ±
1.8 days, respectively, and were 6.3 ± 1.9 days in never
smokers versus 6.5 ± 1.9 days in past or current smokers.
Durations of treatment were 6.0 ± 1.8 days for patients
aged < 50 years, 6.4 ± 1.9 for age ≥ 50 to < 65, 6.7 ± 2.0 days
for age ≥ 65 to < 80, and 7.0 ± 1.9 days for age ≥ 80 years.
The last follow-up visit was performed after a mean of
9.8 ± 6.2 days (range 2–66 days) from the initiation of
Table 1 Patient demographics and disease characteristics
at baseline (efficacy population)





Mean (SD) age, y (n = 2532) 57.8 (12.2)
Mean (SD) weight, kg (n = 2504) 78.8 (15.3)
Mean (SD) height, cm (n = 2477) 170.4 (8.5)







Frequency of common symptoms, n (%)
Sputum purulence increased 2021 (79.7)
Worsening dyspnea 1998 (78.8)
Sputum volume increased 1707 (67.3)
Upper respiratory tract infection (past 5 days) 1266 (49.9)
Anthonisen grade, n (%)
Type I 1089 (42.9)
Type II 1019 (40.2)
Type III 412 (16.2)
Missing 16 (0.6)
Smoking status, n (%)
Past or current 1367 (53.9)
Never 1159 (45.7)
Missing 10 (0.4)
Years with chronic bronchitis, n (%)
< 1 127 (5.0)
1-5 863 (34.0)
> 5-10 748 (29.5)
> 10 796 (31.4)
Missing 2 (0.1)








≥ 6 109 (4.3)
Missing 10 (0.4)
Hospitalization due to AECB in past 12 months
None 1867 (73.6)
Table 1 Patient demographics and disease characteristics






≥ 5 17 (0.7)
Missing 1 (< 0.1)
Corticosteroid intake in past 12 months
Yes 964 (38.0)
No 1571 (61.9)
Missing 1 (< 0.1)




AECB, acute exacerbation of chronic bronchitis.
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prematurely in 23 (0.9%) patients, because of the
patient’s decision (n = 4), insufficient efficacy (n = 3), ad-
verse events (n = 9), and ‘other reasons’ (n = 8) (multiple
responses included).
Efficacy assessments of moxifloxacin treatment
An improvement or relief of the symptoms of AECB that
were present at baseline was reported in 89.4% of
patients for sputum volume, 97.2% for fever, 86.0% for
cough, 87.7% for dyspnea, and 77.2% for sputum charac-
ter during moxifloxacin treatment. Additional symptom
changes are presented in Table 3.
Improvement in symptoms occurred after a mean of
3.4 ± 1.4 days of moxifloxacin treatment. Improvements
occurred by 3 days in 60.7% of patients, 5 days in 93.2%,
and 10 days in 99.3%. Only 0.6% of patients (n = 14)
experienced no symptom improvements during the ob-
servational period.
The mean duration of treatment until symptom im-
provement in patients with Anthonisen type I, II, and III
AECB was 3.6 ± 1.5, 3.3 ± 1.4, and 3.4 ± 1.4 days, respect-
ively (Table 4), 3.4 ± 1.4 days in never smokers versus
3.5 ± 1.5 days in past or current smokers, 3.6 ± 1.6 days in
concomitant corticosteroid users versus 3.4 ± 1.3 in non-
corticosteroid users, and 3.7 ± 1.5 days in patients with >3
exacerbations versus 3.4 ± 1.4 days in patients with ≤3
exacerbations in the previous 12 months. Duration of
treatment until symptom improvement was 3.2 ± 1.4 days
in patients aged < 50 years, 3.4 ± 1.4 days for age ≥ 50 to
< 65, 3.6 ± 1.5 days for age ≥ 65 to < 80, and 3.7 ± 1.9 for
age ≥ 80 years. Mean duration of treatment until symptom
improvement in patients with concomitant diseases is
Table 2 Impact of current AECB episode on daily life activities and sleep disturbance (efficacy population)
Parameter Days with impact on daily life activities Nights with sleep disturbance
(N = 2292) (N = 1740)
n (%) Mean SD n (%) Mean SD
Gender
Male 1308 (57.1) 6.6 5.3 971 (55.8) 4.1 3.8
Female 984 (42.9) 6.6 5.8 769 (44.2) 4.1 3.6
Missing 0 (0) - - 0 (0) - -
Age group (years)
≥ 35 to < 50 615 (26.8) 6.4 5.2 406 (23.3) 3.7 2.7
≥ 50 to < 65 922 (40.2) 6.7 5.9 712 (40.9) 4.0 4.1
≥ 65 to < 80 680 (29.7) 6.7 5.3 557 (32.0) 4.5 3.8
≥ 80 71 (3.1) 5.8 3.9 63 (3.6) 4.3 3.0
Missing 4 (0.2) 11.8 5.2 2 (0.1) 4.0 1.4
Smoking status
Never 1027 (44.8) 6.7 5.6 786 (45.2) 4.0 3.7
Past or current smoker 1255 (54.8) 6.5 5.4 945 (54.3) 4.2 3.7
Missing 10 (0.4) 8.7 5.3 9 (0.5) 3.6 2.1
Concomitant diseases of special interest
COPD 1549 (67.6) 6.6 5.6 1216 (69.9) 4.3 3.9
Asthma 389 (17.0) 7.5 6.8 331 (19.0) 4.4 3.5
Emphysema 568 (24.8) 7.7 6.4 461 (26.5) 4.5 3.7
Bronchiectasis 151 (6.6) 7.3 6.9 128 (7.4) 4.6 4.7
Cor pulmonale 251 (11.0) 8.1 6.4 222 (12.8) 5.1 4.2
Cardiomyopathy 146 (6.4) 7.9 7.4 122 (7.0) 5.4 5.0
Cardiac ischemia 544 (23.7) 7.2 6.3 429 (24.7) 4.2 3.5
Heart insufficiency 135 (5.9) 10.9 10.1 126 (7.2) 6.4 6.3
Cardiac arrhythmia 145 (6.3) 7.7 5.1 131 (7.5) 4.9 4.0
Chronic alcoholism 39 (1.7) 6.0 6.8 24 (1.4) 5.3 5.5
Diabetes 238 (10.4) 6.3 5.3 196 (11.3) 4.1 3.2
No diseases of special interest 324 (14.1) 5.8 4.1 203 (11.7) 3.0 2.8
Anthonisen grade
Type I 1014 (44.2) 7.1 5.1 793 (45.6) 4.5 3.8
Type II 913 (39.8) 6.5 5.9 666 (38.3) 3.8 3.6
Type III 353 (15.4) 5.6 5.6 274 (15.7) 3.6 3.3
Missing 12 (0.5) 7.4 6.2 7 (0.4) 7.3 7.5
Number of severe symptoms per patient at start of therapy
1 446 (19.5) 6.0 5.2 295 (17.0) 3.5 3.5
2 596 (26.0) 6.0 5.0 417 (24.0) 3.5 3.3
3 377 (16.4) 6.3 5.0 279 (16.0) 4.1 3.1
4 241 (10.5) 6.8 5.4 193 (11.1) 4.4 3.9
5 163 (7.1) 7.7 4.9 142 (8.2) 4.9 3.4
6 142 (6.2) 10.2 7.9 141 (8.1) 5.8 3.7
7 66 (2.9) 9.6 7.5 66 (3.8) 6.2 5.8
8 16 (0.7) 10.4 9.6 15 (0.9) 8.1 8.6
None 245 (10.7) 5.6 4.6 192 (11.0) 3.2 3.1
AECB, acute exacerbation of chronic bronchitis; COPD, chronic obstructive pulmonary disease.
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Table 3 Course of symptoms during observational period; patients with symptoms at initial visit (efficacy population)
Symptom Total Relieved Improved Unchanged Worsened Missing
n (%)a n (%)b n (%)b n (%)b n (%)b n (%)b
Fever 1768 (69.7) 1713 (96.9) 5 (0.3) 15 (0.8) 0 (0.0) 35 (2.0)
Cough 2512 (99.1) 1666 (66.3) 495 (19.7) 320 (12.7) 1 (< 0.1) 30 (1.2)
Dyspnea 2298 (90.6) 1615 (70.3) 399 (17.4) 245 (10.7) 1 (< 0.1) 38 (1.7)
Sputum volume 2471 (97.4) 1364 (55.2) 846 (34.2) 226 (9.1) 8 (0.3) 27 (1.1)
Sputum character 2284 (90.1) 1350 (59.1) 446 (19.5) 73 (3.2) 1 (< 0.1) 414 (18.1)
Chest discomfort 2116 (83.4) 1822 (86.1) 103 (4.9) 152 (7.2) 1 (< 0.1) 38 (1.8)
Fatigue 1984 (78.2) 1573 (79.3) 180 (9.1) 186 (9.4) 0 (0.0) 45 (2.3)
Sleep disturbances 1672 (65.9) 1521 (91.0) 45 (2.7) 78 (4.7) 1 (0.1) 27 (1.6)
aProportion of the efficacy population (n = 2536); bproportion of the patients who had symptoms at initial visit.
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by the attending physician), the mean duration of moxi-
floxacin treatment until improvement was 3.5 ± 1.4 days.
The mean duration until attainment of a symptom-free
status was 6.5 ± 2.7 days. A total of 49.1% of patients were
symptom-free after 5 days, 77.6% after 7 days, 93.5% after
10 days, and 98.3% after 20 days (Figure 2). Only 1.4% of
observed patients (n = 36) were reported not to attain
symptom-free status during the observational period.
Safety assessments
Treatment-emergent adverse events (TEAEs) were re-
ported in 2.13% (n = 57) patients during the observational
period. The most common TEAEs included diarrhea






Type I 1084 3.6 (1.5)
Type II 1011 3.3 (1.4)
Type III 409 3.4 (1.4)
Missing 16 4.2 (1.6)
Concomitant diseases of special interest
COPD 1667 3.5 1.4
Asthma 412 3.4 1.4
Emphysema 602 3.6 1.5
Bronchiectasis 162 3.8 1.4
Cor pulmonale 268 3.6 1.4
Cardiomyopathy 157 3.5 1.5
Cardiac ischemia 582 3.7 1.6
Heart insufficiency 138 3.1 1.3
Cardiac arrhythmia 151 3.7 1.6
Diabetes 255 3.6 1.7
COPD, chronic obstructive pulmonary disease.(0.30%, n = 8), dyspepsia (0.22%, n = 6), fatigue (0.15%,
n = 4), and headache (0.15%, n = 4). TEAEs considered po-
tentially drug related were reported in 1.91% (n = 51)
patients. Moxifloxacin treatment was interrupted in eight
of these patients, withdrawn in four, and the dose was
reduced in one patient. By the end of the observational
period, drug-related TEAEs had resolved in 40 of the 51
patients, resolved with sequelae in another three, and
improved in eight patients.
Four patients (0.15%) experienced 11 serious TEAEs
(n = 2, atrial fibrillation; n = 1 each of: acute myocardial
infarction, cardiac flutter, diplopia, vomiting, allergic
edema, amnesia, dizziness, dyspnea, and skin reaction).
The serious TEAEs were considered to be drug related.
All serious TEAEs had resolved by the end of the obser-
vational period, following interruption of moxifloxacin
treatment in three patients and treatment withdrawal in
one patient.
None of the 10 patients who received moxifloxacin at
above the recommended dose of 400 mg once daily (n = 5,
600 mg/day; n = 5, 800 mg/day) experienced an adverse
event.
Summary assessments of moxifloxacin treatment
The efficacy of moxifloxacin was rated by physicians as
‘very good’ or ‘good’ in 97.7% of patients, ‘sufficient’ in
1.8%, and ‘insufficient’ in 0.5%. Physicians’ assessments
of the efficacy of moxifloxacin in patient subgroups cate-
gorized by gender, age, and Anthonisen grade are
presented in Table 5. The tolerability of moxifloxacin
was rated by physicians as ‘very good’ or ‘good’ in 97.8%
of patients, ‘sufficient’ in 1.8%, and ‘insufficient’ in 0.3%.
Approximately 99% of both physicians and patients
stated that they were ‘very satisfied’ or ‘satisfied’ with the
therapeutic effect of moxifloxacin. Compared with the
antibiotic treatment during the previous episode of
AECB, physicians rated moxifloxacin as better in 77.5%
of patients, equal in 5.3%, and worse in 0.2%, with miss-
ing data in 17.0%. Moxifloxacin was considered to have
an earlier onset of action compared with the previous
Figure 2 Cumulative increase in proportion of symptom-free patients during moxifloxacin treatment.
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and later onset in 1.3%, with missing data in 15.7%.
Physicians reported that they would prescribe moxifloxa-
cin again in 98.1% of patients.
Discussion
This non-interventional, naturalistic observational study
enrolled a large cohort of outpatients (n = 2672) withTable 5 Physician’s assessments of efficacy of
moxifloxacin (efficacy population)
Parameter Total Very good / good Sufficient Insufficient
n n (%) n (%) n (%)
Gender
Male 1441 1405 (97.5) 30 (2.1) 6 (0.4)
Female 1095 1072 (97.9) 15 (1.4) 7 (0.6)
Missing 0 0 (0) 0 (0) 0 (0)
Age group (years, n = 2462)
≥ 35 to < 50 707 694 (98.2) 9 (1.3) 4 (0.6)
≥ 50 to < 65 1023 999 (97.7) 20 (2.0) 4 (0.4)
≥ 65 to < 80 728 707 (97.1) 15 (2.1) 5 (0.7)
Missing 4 4 (100) 0 (0) 0 (0)
Anthonisen grade
Type I 1089 1065 (97.8) 17 (1.6) 7 (0.6)
Type II 1019 995 (97.6) 21 (2.1) 3 (0.3)
Type III 412 401 (97.3) 7 (1.7) 3 (0.7)
Missing 16 16 (100) 0 (0) 0 (0)AECB, Anthonisen types I to III, to receive moxifloxacin
treatment at the recommended dose of 400 mg once
daily. A special feature of the study is the well-
documented patient history regarding previous AECBs,
concomitant diseases, and comedications related both to
the underlying respiratory disease as well as to other
comorbidities before study entry. The majority of
patients (approximately 80%) had experienced an exacer-
bation within the previous 12 months. Also reflecting
current clinical experience, a large proportion of the
patients had an underlying respiratory condition (e.g.
COPD, emphysema, or asthma).
Moxifloxacin administered for a mean of 6.4 days
(range 1–15 days) was a highly effective treatment in
these patients. Individual symptoms and signs of sputum
volume, fever, cough, dyspnea, and sputum character
resolved or improved in the majority of patients (range
77-89%) during the observational period. Improvements
in symptoms occurred after a mean of 3.4 days and over
93% of patients were symptom-free after 10 days. No dif-
ferences in the efficacy of moxifloxacin were observed
between patients either without or with a diverse range
of comorbidities.
Unlike in clinical trials, the dosing regimen used in this
non-interventional study was left to the sole discretion of
the treating physician. It is interesting to note the high
rate of physician compliance (99.6%) with the dose recom-
mended in the Summary of Product Characteristics. This
suggests that physicians considered the recommended
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need to adjust the dose, e.g. for body weight. The lack of
need for dose adjustment has the advantages of easier dos-
ing and a reduced risk of overdosing.
The results of this study are in agreement with previ-
ous studies of moxifloxacin treatment in patients with
AECB, including the international observational GIANT
study, where symptom improvement occurred after a
mean of 3.4 days [29]. Physicians’ summary assessments
of moxifloxacin were also similar in the two studies, in-
cluding a rating of ‘very good or good’ in excess of 95%
of patients.
The rapid recovery from symptoms observed in this
study is a desirable characteristic of an effective treat-
ment for patients with AECB. Other observational and
controlled studies and cross-sectional analyses report
that moxifloxacin is associated with a more rapid recov-
ery from symptoms than other commonly used treat-
ments [31-33]. The mean duration of treatment until
symptom improvement in the current study was broadly
similar among patients, but with a trend to increased
treatment duration in patients with greater AECB sever-
ity, concomitant diseases, and older age.
Physicians rated the tolerability of moxifloxacin as
‘very good or good’ in approximately 98% of patients,
similar to the rate (97%) reported in the observational
study by Miravitlles et al. [29]. Incidences of TEAEs and
drug-related adverse events were low. The incidence of
TEAEs was lower in the current study than reported in
controlled clinical studies (e.g. [34]), which may be
attributed to an underreporting of mild/moderate ad-
verse events that is a feature of observational studies.
The profile of adverse events reported in this study is
in agreement with current knowledge of this antibiotic
[25,29,35,36]. A meta-analysis of clinical trial and post-
marketing surveillance data for moxifloxacin identified
nausea, dizziness, and diarrhea as the most frequent ad-
verse events, which occurred at a rate similar to com-
parator medications [35]. For most patients in the
current study, adverse events resolved during the course
of treatment and were associated with low rates of treat-
ment withdrawal (0.4%). The observational study by
Miravitlles et al. [29] reported similarly low rates of
treatment-related withdrawal (0.6%).
The overall satisfaction with moxifloxacin treatment
expressed by both physicians and patients was high.
Relative to previous antibiotics, moxifloxacin also pro-
vided a superior efficacy and a faster onset of effect in
the majority of patients.
Notable demographic and disease characteristics of
this population from South Eastern/Eastern Europe in-
clude a markedly higher incidence of COPD among
non-smokers when compared with data from Western
Europe and the USA [37-39]. This indicates thatadditional environmental factors, such as high levels of
industrial air pollution and/or occupational or home in-
door air pollution, contributed to the development of
COPD in patients from the participating countries, as
described by Mannino and Buist [40].
Limitations of the current study include the primary
role of physician judgment for decisions on patient
selection and management; the absence of a control
group to quantify the response to other antibacterial
agents; and the lack of bacteriological assessment, which
precludes a correlation with the clinical outcomes. All
prescribing choices were made by physicians. As ap-
proximately 16% of patients who received moxifloxacin
were classified with Anthonisen type III AECB, anti-
biotic therapy was not prescribed in accordance with
current guidelines in all circumstances. A similar experi-
ence was reported in the GIANT study [29].
A strength of observational studies is that they provide
an important accompaniment to randomized controlled
trials and reflect real-world practice in terms of prescri-
bing behavior [41]. The lack of bacteriological assess-
ment in this study is in line with current practice for the
outpatient treatment of AECB. The high response rate
in this study, which included patients with a range of
common comorbidities, suggests that treatment with
broader-spectrum drugs such as moxifloxacin is appro-
priate for patients with moderate-to-severe AECB who
are managed outside hospital.
Conclusions
The efficacy, safety, and tolerability profiles of moxifloxa-
cin that are characterized in this large observational study
from South Eastern/Eastern Europe confirm previous
studies which report that moxifloxacin offers benefits for
the treatment of moderate-to-severe exacerbations in
outpatients with AECB. The response to moxifloxacin
treatment was broadly independent of the patients’ demo-
graphic and disease background. Physicians complied with
the recommended 400 mg once-daily dose in a large
proportion of patients, confirming the advantages of this
simple dosing regimen.
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